A new market study, titled “Bleeding Disorders Treatment – Global Market Outlook (2017-2026)”, has been featured on WiseGuyReports.
According to research report, the Global Bleeding Disorders Treatment Market is accounted for $11.14 billion in 2017 and expected to grow at a CAGR of 8.4% to reach $23.04 billion by 2026. Factors like growth in R&D investment for hemophilia products, inclination towards prophylactic treatment, increasing number of hemophilia patients, and the emergence of Biosimilars product are fuelling the market growth. Patent expiry of existing brands provide generic drug manufacturers an opportunity to enter, as well as sustaining healthcare infrastructure in developing economies with advancement in technology for development of new drugs and therapies will provide ample opportunity for the market growth. Market will also witness emerging trends like high entry barriers created by local government and low switching rate for hemophilia products. However, high cost of hemophilia drugs and inadequate reimbursement and lack of availability of skilled professionals are hampering the market growth.
By type, Hemophilia is a genetic disorder characterized by spontaneous hemorrhage or prolonged bleeding due to factor VIII or IX deficiency. Patients with more severe haemophilia suffer more severe and more frequent bleeds. Hemophilia is inherited in an X-linked recessive manner. The main therapy to treat hemophilia A is concentrated FVIII product, as clotting factor or simply factor. DDAVP (desmopressin acetate) is the synthetic version of vasopressin, a natural antidiuretic hormone that helps stop bleeding. Emerging trends in therapies are efficacy and safety assessments of established extended half-life (EHL) factor products and interest in Clinical trial data from new/emerging EHL factor products and nonfactor replacement therapies.
Based on Drug, Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. There are a few clotting factor concentrates that are rich in VWF. The management of patients affected by rare bleeding disorders (RBDs) is still a critical challenge. The development of alternative therapeutics, such as anti-tissue factor pathway inhibitor, ALN-AT3, and ACE910, for patients with hemophilia might also help in the treatment of patients affected by RBDs. FDA approved Vonvendi, which is produced with a genetically engineered Chinese hamster ovary cell line that expresses von Willebrand factor and the blood-clotting protein factor VIII.
North America is attributed to dominate the market during the forecast period owing to high acceptance for prophylaxis treatment among all age groups in the U.S. However, Asia Pacific is projected to grow at highest CAGR during the forecast period, due to increasing awareness of these disorders and availability of cheap generic drugs in the emerging economies such as India and China.
Some of the key players in Global Bleeding Disorders Treatment Market are Alnylam Pharmaceuticals, Amgen, Inc, Baxalta (Now Shire), Bayer Pharmaceuticals, Biogen Inc, Bristol-Myers Squibb Company, Cangene Corporation, CSL Behring, Grifols SA, Janssen Pharmaceuticals, Novo Nordisk A/S, Octapharma, Pfizer Inc., Sanofi and Xenetic Biosciences, Inc.
- Fibrin Sealants
- Plasma-derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrates
- Other Drugs
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Clotting Factor Deficiency
- Medication Treatments
- Replacement Therapies
- North America
o Rest of Europe
- Asia Pacific
o New Zealand
o South Korea
o Rest of Asia Pacific
- South America
o Rest of South America
- Middle East & Africa
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
What our report offers:
– Market share assessments for the regional and country level segments
– Market share analysis of the top industry players
– Strategic recommendations for the new entrants
– Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
– Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
– Strategic recommendations in key business segments based on the market estimations
– Competitive landscaping mapping the key common trends
– Company profiling with detailed strategies, financials, and recent developments
– Supply chain trends mapping the latest technological advancements
Table of Content
1 Executive Summary
3 Market Trend Analysis
4 Porters Five Force Analysis
5 Global Bleeding Disorders Treatment Market, By Drug
6 Global Bleeding Disorders Treatment Market, By Type
7 Global Bleeding Disorders Treatment Market, By Therapy
8 Global Bleeding Disorders Treatment Market, By Geography
9 Key Developments
10 Company Profiling
10.1 Alnylam Pharmaceuticals
10.2 Amgen, Inc
10.3 Baxalta (Now Shire)
10.4 Bayer Pharmaceuticals
10.5 Biogen Inc
10.6 Bristol-Myers Squibb Company
10.7 Cangene Corporation
10.8 CSL Behring
10.9 Grifols SA
10.10 Janssen Pharmaceuticals
10.11 Novo Nordisk A/S
10.13 Pfizer Inc.
10.15 Xenetic Biosciences, Inc
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)